Companies /Healthcare

FORTE SOFTWARE INC

NASDAQ: FTRE Biotechnology
$19.59
▼ $0.20 (−1.01%) today
Markets closed · 3:50am ET

FTRE at a Glance

Valuation
Market cap
$1.9B
Profitability
Revenue (TTM)
$2.7B
Profit margin
-2.6%
EPS (TTM)
$-0.72
Price
52-week range
$9 – $26
Street target
$23.62

Headquartered in Durham, NC Fiscal year ends December NASDAQ: FTRE fortrea.com

About Fortrea Holdings

Fortrea Holdings Inc. is a contract research organization (CRO) providing clinical development solutions to the life sciences industry. It serves emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies. Its services include phase I-IV clinical trial management, clinical pharmacology and consulting. These are delivered through full-service, functional service provider (FSP) and hybrid models. The company draws on three decades of experience across more than 20 therapeutic areas, an investigator site network and technology capabilities, with staff working in about 100 countries. Fortrea was spun off from its former parent and has since sold its Enabling Services Segment. It has acquired the Early Phase Services division of Worldwide Clinical Trials and is investing in early clinical development and technology under a return-to-growth strategy. As of September 30, 2026, it reported backlog of $7,316 million after a $558 million downward adjustment, and a trailing twelve-month book-to-bill of 1.12x. Updated

Latest Activity

FTREFortrea Holdings
Q3 2026
EPS
$0.28
est $0.22+28.9%
Revenue
$692M
est $672M+3.0%

Cost cuts turned a revenue decline into the fourth straight quarter of rising earnings, and management raised the midpoints of full-year revenue and adjusted EBITDA guidance. The catch sitting under the beat: a contract review stripped $558 million out of backlog.

Quarterly EPS — reported vs estimate
FTREFortrea Holdings Inc
Reports Thu Oct 29Before openConfirmed

Fortrea reports at 6:30 AM ET with two straight EPS beats behind it, but only 2 of the last 4 quarters cleared the bar. Consensus sits at $0.22 per share on $671.5 million in revenue, the number that decides whether the CRO recovery is real.

    FTRE Coverage

    Frequently Asked Questions

    What does Fortrea Holdings do?

    Fortrea Holdings Inc. is a contract research organization (CRO) providing clinical development solutions to the life sciences industry. It serves emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies.

    What is the FTRE stock price target?

    The Wall Street consensus 12-month price target for FTRE is $23.62.